doi:10.3969/j.issn.1673-8640.2026.08.017

Abstract

CLC Number:

R446.1

Figures/Tables 1

References 17

[1]	Grinfeld J, Nangalia J, Baxter E J, et al. Classification and personalized prognosis in myeloproliferative neoplasms[J]. N Engl J Med, 2018, 379(15):1416-1430.
[2]	Luque Paz D, Kralovics R, Skoda R C. Genetic basis and molecular profiling in myeloproliferative neoplasms[J]. Blood, 2023, 141(16):1909-1921.
[3]	Makarik T V, Abdullaev A O, Nikulina E E, et al. Low JAK2 V617F allele burden in ph-negative chronic myeloproliferative neoplasms is associated with additional CALR or MPL gene mutations[J]. Genes(Basel), 2021, 12(4):559.
[4]	蒋玲琳, 李曼倩, 常银银, 等. 骨髓增殖性肿瘤JAK2基因和CALR基因突变双表达3例并文献复习[J]. 重庆医学, 2023, 52(17):2713-2716.
[5]	Scott L M, Tong W, Levine R L, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis[J]. N Engl J Med, 2007, 356(5):459-468.
[6]	Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia:2021 update on diagnosis,risk-stratification and management[J]. Am J Hematol, 2020, 95(12):1599-1613.
[7]	Nangalia J, Massie C E, Baxter E J, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2[J]. N Engl J Med, 2013, 369(25):2391-2405.
[8]	Klampfl T, Gisslinger H, Harutyunyan A S, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms[J]. N Engl J Med, 2013, 369(25):2379-2390.
[9]	Lasho T L, Finke C M, Tischer A, et al. Mayo CALR mutation type classification guide using alpha helix propensity[J]. Am J Hematol, 2018, 93(5):E128-E129.
[10]	Haunstrup L M, Ebbesen L H, Hansen M, et al. Skewed ratio between type 1 and type 2 calreticulin mutations in essential thrombocytosis patients with concomitant Janus kinase 2 V617F mutation[J]. Exp Hematol, 2018, 68:62-65.
[11]	Thompson E R, Nguyen T, Kankanige Y, et al. Clonal independence of JAK2 and CALR or MPL mutations in comutated myeloproliferative neoplasms demonstrated by single cell DNA sequencing[J]. Haematologica, 2021, 106(1):313-315.
[12]	Nishimura M, Nagaharu K, Ikejiri M, et al. Acquisition of JAK2 V617F to CALR-mutated clones accelerates disease progression and might enhance growth capacity[J]. Br J Haematol, 2021, 194(5):e89-e92.
[13]	Perner F, Perner C, Ernst T, et al. Roles of JAK2 in aging,inflammation,hematopoiesis and malignant transformation[J]. Cells, 2019, 8(8):854.
[14]	Wang Y, Ran F, Lin J, et al. Genetic and clinical characteristics of patients with philadelphia-negative myeloproliferative neoplasm carrying concurrent mutations in JAK2V617F,CALR,and MPL[J]. Technol Cancer Res Treat, 2023, 22:15330338231154092.
[15]	Lim K H, Chang Y C, Gon-shen Chen C, et al. Frequent CALR exon 9 alterations in JAK2 V617F-mutated essential thrombocythemia detected by high-resolution melting analysis[J]. Blood Cancer J, 2015, 5(3):e295.
[16]	Schueller C M, Majoros A, Nivarthi H, et al. Co-expression of mutated Jak2 and Calr enhances myeloproliferative phenotype in mice without loss of stem cell fitness[J]. Am J Hematol, 2022, 97(11):E396-E399.
[17]	Tefferi A, Vannucchi A M, Barbui T. Essential thrombocythemia:2024 update on diagnosis,risk stratification,and management[J]. Am J Hematol,2024, 99(4):697-718.

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 1

References 17

Related Articles 15

Recommended Articles

Metrics

[1]	MIAO Weiye, Sareguli·abulimiti , MA Cheng. Plasma D-dimer and platelet-derived growth factor-D for assessing intracranial hematoma expansion in hemorrhagic stroke patients [J]. Laboratory Medicine, 2026, 41(8): 806-810.
[2]	LIU Chengguo, LI Yuanyuan, LI Shaowei, CHEN Kai, ZHU Xianyou. Role of combined determination of miR-100，miR-148a，β-CTX，tP1NP and BGP in osteoporotic fractures [J]. Laboratory Medicine, 2026, 41(8): 787-792.
[3]	HAO Wanjiao, XUE Huiling, HAO Yumei, SONG Nan, CHEN Yun, REN Xiaopang. Relationship between serum α-klotho protein levels in patients with PCOS and glucose and lipid metabolism [J]. Laboratory Medicine, 2026, 41(8): 763-768.
[4]	FENG Shengjuan, ZHAO Qingyi, ZHOU Limin, CHAI Zhijie, SUN Sihang, SHANG Ayong, WEN Ronghua. Serum CHI3L1，STAT3 and TSG-6 levels in monitoring the condition and wound healing degree of burn patients [J]. Laboratory Medicine, 2026, 41(8): 757-762.
[5]	LIANG Min, SUN Daqing, ZHOU Nan, WANG Li. Clinical value of serum syndecan-1 and Caspase-1 in the diagnosis and disease assessment of Kawasaki disease [J]. Laboratory Medicine, 2026, 41(8): 744-749.
[6]	WANG Lixian, GUO Na, SONG Ran, CHEN Limi, WANG Xiaojing. Roles of serum PARK7 and sTLT-1 in the short-term prognosis assessment of patients with severe pneumonia complicated by respiratory failure [J]. Laboratory Medicine, 2026, 41(8): 729-736.
[7]	ZHAO Jinyan, PENG Xia, LI Yaohua, ZHANG Ying, YU Wenfang. Role of combined determination of intraocular fluid immunophenotyping，IL-10/IL-6 ratio and MYD88 gene L265P mutation in the diagnosis of PVRL [J]. Laboratory Medicine, 2026, 41(8): 723-728.
[8]	DING Xueqing, LIU Yu, TENG Jisen, CAO Wenjun, KONG Xiangmei, WANG Zhujian. Role of aqueous humor matrix metalloproteinase-3 in the differential diagnosis of glaucoma subtypes [J]. Laboratory Medicine, 2026, 41(7): 621-624.
[9]	GUO Meifeng, NI Leilei, ZHANG Xinyuan, WANG Guiqin, LI Jihan. Influence of serum levels of YKL-40，NGAL and SOCS1 in patients with multidrug-resistant tuberculosis after treatment on the conversion of sputum bacteria to negative state [J]. Laboratory Medicine, 2026, 41(7): 625-630.
[10]	GAO Yuting, HOU Ze, ZHANG Yuxin, WANG Mengwei, LIAN Entao, WANG Xinyi, YE Yingnan, JIA Kegang. Prognostic value of the ratio of neutrophil-to-high-density lipoprotein cholesterol ratio in patients with heart failure with reduced ejection fraction [J]. Laboratory Medicine, 2026, 41(7): 643-649.
[11]	ZHANG Xue, LI Yue, CHE Yongjun, ZHOU Xiaohong. Correlation between serum SOST，CHI3L1 and CYR61 levels and bone metabolism in patients with hyperthyroidism [J]. Laboratory Medicine, 2026, 41(7): 650-656.
[12]	YE Kai, QUAN Heng, NIU Ziguang, LI Yanning, XIA Dongge, WENG Yiyi, ZHANG Lei. Role of combined determination of AVDL and LOI in short-term prognosis assessment of ACI patients [J]. Laboratory Medicine, 2026, 41(7): 657-663.
[13]	JIANG Yongli, LI Aihua, SHENG Chenglan. Relationship between serum 25-hydroxyvitamin D，creatinine/cystatin C ratio and sarcopenia in elderly patients with type 2 diabetes mellitus [J]. Laboratory Medicine, 2026, 41(7): 664-669.
[14]	YU Mengyao, WANG Chunyan, QIAO Rui, HUANG Shengkai, GONG Hengwen, CUI Chanjuan. Research progress on the relationship between platelets and complements [J]. Laboratory Medicine, 2026, 41(7): 708-713.
[15]	LI Benbo, YAN Shengkai. Standardization of clinical blood lipid testing：from guidelines to practice [J]. Laboratory Medicine, 2026, 41(6): 517-520.